丙型肝炎直接抗病毒药物的发展现状
병형간염직접항병독약물적발전현상
Status quo and progress in the development of direct-acting antiviral agents against hepatitis C
  • 万方数据
    国际流行病学传染病学杂志 국제류행병학전염병학잡지
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
    2014年 6期 412-415 ,共4页

    戴明佳%方圆%李春杨%颜学兵

    대명가%방원%리춘양%안학병

    肝炎,丙型%直接抗病毒药物%蛋白酶抑制剂%聚合酶抑制剂 肝炎,丙型%直接抗病毒藥物%蛋白酶抑製劑%聚閤酶抑製劑
    간염,병형%직접항병독약물%단백매억제제%취합매억제제
    Hepatitis C%Direct-acting antiviral agents%Protease inhibitors%Polymerase inhibitors
    慢性丙型肝炎的标准化治疗方案为聚乙二醇IFN联合利巴韦林,但其疗效欠佳,而口服直接抗病毒药物(DAA)的问世给患者带来了新的希望.目前已经上市或在研的DAA主要包括NS3/4A蛋白酶抑制剂、NS5A蛋白酶抑制剂和NS5B聚合酶抑制剂等.此文对这3种DAA的发展现状及其进展作一综述.
    만성병형간염적표준화치료방안위취을이순IFN연합리파위림,단기료효흠가,이구복직접항병독약물(DAA)적문세급환자대래료신적희망.목전이경상시혹재연적DAA주요포괄NS3/4A단백매억제제、NS5A단백매억제제화NS5B취합매억제제등.차문대저3충DAA적발전현상급기진전작일종술.
    Pegylated-interferon combined with ribavirin is considered as the standard treatment of chronic hepatitis C,but the efficacy is limited.The advent of direct-acting antiviral agents (DAAs)brings new hope to patients infected with HCV.DAAs on the market or under research can be mainly classified into NS3/4A protease inhibitors,NS5A protease inhibitors,and NS5B polymerase inhibitors.This article reviews the progress in the development of DAAs.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문